Text Size: A A A      Contrast:        Transparency in Coverage Rule

Squalamine Eye Drops have big impact on AMD study patients

Exciting Results from Squalamine Eye Drops Study for the Treatment of Wet AMD

 Over half of the enrolled patients in Ohr Pharmaceuticals’ Squalamine Eye Drops study have now completed their study follow-up, and the planned interim analysis results are generating a lot of excitement for ophthalmologists around the country!  

Retina Associates of Cleveland, Inc (RACI) is the only clinical site in Ohio offering the new drops to qualified patients enrolled in the randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of the new treatment for wet AMD.  So far the study has shown a 65% greater relative benefit with usage of squalamine drops plus Lucentis injections, versus those receiving placebo drops with Lucentis (Lucentis alone).  Lucentis is an FDA approved, anti-VEGF (vascular endothelial growth factor) medication injected monthly or as-needed into the eye by an ophthalmologist, and is routinely used in many patients with wet AMD as a current standard of treatment.

Many more patients actually gained 3 to 5 lines of vision with use of squalamine plus Lucentis, versus Lucentis alone.  “We are hopeful about squalamine’s potential to minimize the progression of wet AMD, the leading cause of blindness in people over 50 in the U.S.,” stated Lawrence J. Singerman, MD, of Retina Associates.  Dr. Singerman is a principal investigator for this research study at RACI and is on the scientific advisory board for Ohr Pharmaceuticals. 

For more information on this study, please call Retina Associates’ Beachwood office at (216)831-5700.  The full Press Release from Ohr can be found here:http://content.stockpr.com/_news/ohrpharmaceutical/2014-06-24_Ohr_Pharmaceutical_Announces_Positive_Interim_Top__224.pdf